{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"2.97","value":"1.98"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"2.05","value":"2.00"},{"groupId":"OG002","lowerLimit":"0.50","upperLimit":"2.00","value":"1.25"},{"groupId":"OG003","lowerLimit":"0.50","upperLimit":"4.03","value":"1.09"},{"groupId":"OG004","lowerLimit":"0.517","upperLimit":"4.33","value":"1.96"},{"groupId":"OG005","lowerLimit":"1.00","upperLimit":"3.00","value":"1.05"},{"groupId":"OG006","lowerLimit":"1.18","upperLimit":"3.00","value":"2.00"},{"groupId":"OG007","lowerLimit":"0.50","upperLimit":"1.97","value":"1.20"},{"groupId":"OG008","lowerLimit":"1.00","upperLimit":"2.00","value":"1.23"},{"groupId":"OG009","lowerLimit":"1.10","upperLimit":"3.07","value":"2.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"description":"Tmax of PF-06463922 was observed directly from data as time of first occurrence.","dispersionType":"Full Range","groups":[{"description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"10 mg QD (Phase 1)"},{"description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"OG001","title":"25 mg QD (Phase 1)"},{"description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"50 mg QD (Phase 1)"},{"description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"75 mg QD (Phase 1)"},{"description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"100 mg QD (Phase 1)"},{"description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"OG005","title":"150 mg QD (Phase 1)"},{"description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG006","title":"200 mg QD (Phase 1)"},{"description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG007","title":"35 mg BID (Phase 1)"},{"description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG008","title":"75 mg BID (Phase 1)"},{"description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG009","title":"100 mg BID (Phase 1)"}],"paramType":"MEDIAN","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","title":"Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)","type":"SECONDARY","unitOfMeasure":"Hours"}